Medicore, Inc. Reports Third Quarter 2004 Results


HIALEAH, Fla., Nov. 15, 2004 (PRIMEZONE) -- Medicore, Inc. (Nasdaq:MDKI) announced financial results for the first nine months of 2004. Operating revenues for the third quarter of 2004 increased 43% to $11,168,000 compared to $7,807,000 for the same period last year. Operating revenues for the first nine months of 2004 increased 32% to $29,807,000 compared to $22,556,000 for the same period last year.

Pre-tax income for the third quarter of 2004 before minority interest and equity in affiliate earnings was $1,718,000 compared to $652,000 for the same period last year with net income of $649,000 or $.09 per share ($.09 diluted) for the third quarter of 2004 compared to net income of $230,000 or $.04 per share ($.03 diluted) for the same period last year. Pre-tax income for the first nine months of 2004 before minority interest and equity in affiliate earnings was $2,600,000 compared to $1,057,000 for the same period last year with net income of $615,000 or $.09 per share ($.08 diluted) for the first nine months of 2004 compared to net income of $123,000 or $.02 per share ($.01 diluted) for the same period last year. The third quarter of 2004 includes a $402,000 gain on a sale of securities with a $546,000 gain resulting from a sale of a former subsidiary having been recorded during the first half of 2004.

Thomas K. Langbein, Chief Executive Officer and President commented, "Our majority owned subsidiary, Dialysis Corporation of America ("DCA") had a record breaking quarter with a 44% increase in operating revenues and a 152% increase in net income during the third quarter of 2004 and a 33% increase in operating revenues and 112% increase in net income during the first nine months of 2004 compared to the same periods of last year. Pre-operating and initial operating costs are DCA's new centers opened during 2004 was more than offset by improved operating results from its existing centers. DCA expects additional future growth in strategic locations under its controlled expansion program."

The company is primarily engaged in the operation of kidney dialysis centers through DCA, which owns or manages 22 free-standing kidney hemodialysis centers in Georgia, Maryland, New Jersey, Ohio, Pennsylvania, South Carolina and Virginia providing patients with a full range of quality in-center, and at-home dialysis services, as well as providing in-hospital services in many of its markets. DCA has opened four new centers and acquired two centers during 2004, and has two new centers under development in Virginia and Ohio. The company also distributes medical products and has investments in two affiliated Linux software companies.

This release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results and plans to differ materially from those anticipated. Those factors include, but are not limited to, general economic conditions, certain delays beyond the company's control with respect to future business events, the likelihood of realizing the company's investments in the two affiliated Linux software companies, the ability of DCA to timely develop or acquire additional dialysis facilities, whether patient bases of certain of DCA's facilities, particularly its developmental stage facilities, can expand to provide profitability, regulation of dialysis operations, government rate determination for Medicare reimbursement, the highly competitive environment in the operation, development and acquisition of dialysis centers and other risks detailed in the company's filings with the Securities and Exchange Commission, including the company's annual report on Form 10-K for the year ended December 31, 2003. The historical results contained in this press release are not necessarily indicative of future performance of the company.

Medicore, Inc.'s most recent annual report on Form 10-K for the year ended December 31, 2003 and other filings with the Securities and Exchange Commission are available through Medicore's internet home page: http://www.medicore.com.



                       MEDICORE, INC. AND SUBSIDIARIES
                    CONSOLIDATED STATEMENTS OF OPERATIONS
                                 (UNAUDITED)

                    Three Months Ended             Nine Months Ended
                       September 30,                 September 30,
                    ------------------            ------------------
                    2004          2003            2004          2003
                    ----          ----            ----          ----
 Revenues:
 Sales:
  Product
   sales      $   189,694    $   189,703      $   612,840     $   624,484
  Medical
   service
   revenues    10,857,444      7,535,530       28,763,576      21,697,427
               ----------     ----------       ----------      ----------
  Total sales  11,047,138      7,725,233       29,376,416      22,321,911
 Other income     121,173         81,581          430,828         233,816
               ----------     ----------       ----------      ----------
               11,168,311      7,806,814       29,807,244      22,555,727
               ----------     ----------       ----------      ----------
 Cost and
  expenses:
  Cost of sales:
   Cost of
    product
    sales         123,388        115,275          372,638         389,381
   Cost of
    medical
    services    6,051,469      4,706,470       16,951,870      13,425,840
               ----------     ----------       ----------      ----------
  Total cost
   of sales     6,174,857      4,821,745       17,324,508      13,815,221
  Legal fees
   related
   party           89,000         79,000          258,000         238,000
  Selling,
   general and
   administra-
   tive
   expenses      3,407,624      3,128,620       10,202,125       8,212,411
  Provision from
   doubtful
   accounts        303,416          3,424          651,753         258,487
                ----------     ----------       ----------      ----------           
                 9,974,897      8,032,789       28,436,386      22,524,119
                ----------     ----------       ----------      ----------
 Operating
  income(loss)   1,193,414       (225,975)       1,370,858          31,608

 Other income:
  Interest
  income
  related
  parties            1,074          7,560            5,859          22,552
 Gain on sale
  of former
  subsidiary
  (Note)                --             --          545,995              --
 Gain on sale
  of
  securities       402,493        784,005          402,493         784,005
 Other income,
  net              121,482         86,798          275,105         219,008
                ----------     ----------       ----------      ----------
   
                   525,049        878,363        1,229,452       1,025,565
                ----------     ----------       ----------      ----------
 Income before
  income taxes,
  minority
  interest and
  equity in
  affiliate
  earnings       1,718,463        652,388        2,600,310       1,057,173
                ----------     ----------       ----------      ----------
 Income tax
  provision        554,311        252,920        1,048,084         527,271
                ----------     ----------       ----------      ----------              

 Income before
  minority
  interest and
  equity in
  affiliate
  earnings       1,164,152        399,468        1,552,226         529,902
                ----------     ----------       ----------      ----------
 Minority
  interest in
  income of
  consolidated
  subsidiaries    (637,440)      (177,962)      (1,109,931)       (437,708)
                ----------     ----------       ----------      ----------
 Equity in
  affiliate
  earnings         122,375          8,687          172,770          30,320
                ----------     ----------       ----------      ----------

 Net income    $   649,087    $   230,193      $   615,065    $   122,514
                ==========     ==========       ==========     ==========

 Earnings per
  share:
  Basic             $.09          $.04            $.09            $.02
                    ====          ====            ====            ====
  Diluted           $.09          $.03            $.08            $.01
                    ====          ====            ====            ====

 (note) See notes to consolidated  financial statements.


            

Contact Data